EUVIMEDAvasta EUVIMED
Crossref

Meta‐Analysis: Moderate HBV DNA Levels Are Associated With the Highest Risk of Hepatocellular Carcinoma in Chronic Hepatitis B

Jeong‐Ju Yoo, Gi‐Ae Kim, Chang Hun Lee, Moon Haeng Hur, Hyo Young Lee, Han Ah Lee, Ji Won Han, Byeong Geun Song, Won‐Mook Choi, Heechul Nam, Hye Won Lee, Gwang Hyeon Choi and 7 more

Alimentary Pharmacology & Therapeutics · 2026-11-20

DOI: 10.1111/apt.71101 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2026-11-20. Written by Jeong‐Ju Yoo and 18 co-authors. 60 references.

AbstraktBibliograafilised andmedCiteRelated studies

Abstract (original language)

Background and Aims Although serum hepatitis B virus (HBV) DNA levels are generally considered to correlate linearly with hepatocellular carcinoma (HCC) risk in chronic hepatitis B, recent evidence suggests a non‐linear relationship, with peak risk at moderate levels. This systematic review and meta‐analysis aimed to quantitatively assess HCC risk across HBV DNA levels.

Methods

The systematic review and meta‐analysis were reported in accordance with PRISMA 2020. PubMed, Embase, the Cochrane Library, and Web of Science were searched through August 2025. HBV DNA levels were categorized as low (< 3.3 log 10 IU/mL), moderate (3.3–7 log 10 IU/mL), or high (> 7 log 10 IU/mL). The primary outcome was HCC incidence. Hazard ratios (HRs) were synthesized using the generic inverse‐variance method.

Results

A total of 45 studies including 129,950 patients were analysed. Pooled HCC incidence rates per 100 person‐years were 0.304 (95% confidence interval [CI] 0.248–0.361), 0.859 (95% CI 0.751–0.966), and 0.409 (95% CI 0.307–0.511) in the low, moderate, and high HBV DNA groups, respectively. Sensitivity analyses applying a stricter upper HBV DNA threshold and more restrictive classification criteria showed a similar pattern, with the highest pooled incidence in the moderate group. Subgroup analyses by treatment status, HBeAg status, alanine aminotransferase levels, and presence of cirrhosis generally supported the overall pattern. The moderate group carried a higher risk than both the low (pooled HR 2.95, 95% CI 2.41–3.61) and high groups (pooled HR 3.56, 95% CI 2.69–4.72). Meta‐regression further demonstrated a higher HCC incidence rate in the moderate versus high HBV DNA group ( β = 0.350 per 100 person‐years, 95% CI 0.191–0.509; p < 0.001).

Conclusions

Moderate HBV DNA levels were associated with the highest pooled HCC incidence across the predefined categories.

Cite

APA

Yoo, J., Kim, G., Lee, C. H., Hur, M. H., Lee, H. Y., Lee, H. A., Han, J. W., Song, B. G., Choi, W., Nam, H., Lee, H. W., Choi, G. H., Kim, T. H., Lee, Y. B., Kim, B. H., Sinn, D. H., Kim, I. H., Lim, Y., & Chon, Y. E. (2026). Meta‐Analysis: Moderate HBV DNA Levels Are Associated With the Highest Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71101

Vancouver

Yoo J, Kim G, Lee CH, Hur MH, Lee HY, Lee HA, et al. Meta‐Analysis: Moderate HBV DNA Levels Are Associated With the Highest Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71101

BibTeX
@article{Yoo2026,
  author = {Yoo, Jeong‐Ju and Kim, Gi‐Ae and Lee, Chang Hun and Hur, Moon Haeng and Lee, Hyo Young and Lee, Han Ah and Han, Ji Won and Song, Byeong Geun and Choi, Won‐Mook and Nam, Heechul and Lee, Hye Won and Choi, Gwang Hyeon and Kim, Tae Hyung and Lee, Yun Bin and Kim, Bo Hyun and Sinn, Dong Hyun and Kim, In Hee and Lim, Young‐Suk and Chon, Young Eun},
  title = {Meta‐Analysis: Moderate HBV DNA Levels Are Associated With the Highest Risk of Hepatocellular Carcinoma in Chronic Hepatitis B},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.71101}
}
Start for free →